

SARTORIUS



Simplifying Progress



BIA Separations is since November 2020 part of the Sartorius group (Sartorius Stedim Biotech SA at DAX)

About BIA Separations

- The leading developer of monolith technology and the exclusive producer of **CIM® (Convective Interaction Media) monolithic chromatographic columns** for more than 20 years and with > 160 employees currently.
- A specialist in the purification of large biological molecules and viral particles for **gene therapy and the vaccine markets**.
- **Sartorius center of excellence in gene therapy** offers solutions for downstream process development and manufacturing and for analytical methods applicable to multiple large molecules, e.g. AAV, Adeno, Flu, pDNA, mRNA.
- **Supplies unique monolithic chromatographic columns** complimentary to porous particles and membranes.



Expert DSP Bioprocess Development – we can build manufacturing facilities for any Corona vaccine platform

>30 pDNA, mRNA, virus DSP cGMP processes tech transferred to CMOs, sponsors, including Corona.

Product impurities are one of the key reasons for treatment side effects. High purity is therefore mandatory for product safety.

- **pDNA including Corona**, purity is THE key for better transfection and purer mRNA
- Minicircle DNA (shorten the pDNA)
- **ssRNA and dsRNA**, platform process from E.coli to **mRNA** including **Corona**
- **Adeno virus**, more than 20 years experience, including **Corona**
- **AAV vector** (all serotypes, > 20 tested), including **Corona**
- Influenza virus (all serotypes)
- Vaccinia/MVA
- Exosome
- Bacteriophage
- **VLPs** including Flu and **Corona**
- IVIG
- IgM and many more

Testimonials

"We are especially grateful that BIA Separations shared, and operated, with the same sense of urgency we did to help bring gene therapy to the SMA community. BIA's experience with AAV purification and its chromatographic technology were important contributions and we look forward to our continued work together."

Andy Stober, Senior Vice President of Technical Operations for AveXis/Novartis


"We use BIA Separations Monolith columns for the purification of our mRNA drug substance. The Monolith columns come in multiple sizes to meet our needs from small scale product development work to large scale cGMP manufacturing runs. We have found the Monolith columns to provide high throughput and high purity while being very robust and reliable. In addition, BIA Separations has top notch customer service that never fails to impress."

Greg Kubczak, Director of Technical Services and Manufacturing at Arcturus Therapeutics

Key benefits of the integration for BIA Separations

- Financial stability and funds for further development
- Access to global market with on-spot sales and tech support
- Integration of BIA products into Sartorius facility design offerings
- Stronger marketing
- Co-development of new products
- All in all, much faster growth due faster BIA products and technologies acceptance

Long term revenues plan prepared by BIA if integrated with good partner



Very fast expansion plan



- Building A in function since 2011
- Building B in function since June 2021
- Building C to be in function by December 2021
- Building D – plans in preparation

At integrations with giants you get what you fight for only, just nothing is granted.

As in sports Slovenians are in average better in science and technology than most of the other nations, we just need some self confidence, and show it!

Thank you for your attention!

ales.strancar@sartorius.com



SARTORIUS